Feb 6 | News
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-- Merck, known as MSD outside the United States and Canada, today provided an update on the development program for suvorexant, the company's investigational orexin receptor antagonist, which, if approved, will be a new mechanism for the treatment of insomnia.
|
Feb 3 | News
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug.
|
Feb 3 | News
WHITEHOUSE STATION, N.J. (AP) — Merck said Thursday it received U.S. approval for an extended-release version of its diabetes drug Janumet designed to be taken once a day, instead of twice a day.
|
Feb 3 | News
MONTREAL — Montreal's pharmaceutical research cluster is under further threat as global giants adjust to the loss of patent protection for blockbuster drugs and challenges in developing replacements.
|
Feb 2 | News
WHITEHOUSE STATION, N.J. (AP) — Merck & Co. said today that it swung to a fourth-quarter profit because of lower acquisition and restructuring charges and slightly higher sales.
|
Jan 25 | News
The Facility of the Year Awards Judging Panel has named five Category Award Winners and selected one project for Special Recognition in the 2012 Facility of the Year Awards (FOYA) program.
|
Jan 16 | Articles
Vaccines continue to be one of the brighter spots for pharmaceutical companies in the current market, and revenues for vaccine products are expected to continue their double-digit growth in the future.
|
Dec 7 2011 | News
Dendreon said Tuesday that it sold its royalty interest in Merck & Co.’s hepatitis C drug Victrelis (boceprevir) for $125 million in a move that is expected to strengthen the company’s cash holdings.
|
Dec 6 2011 | News
Merck & Co., Inc., known as MSD outside the United States and Canada, today announced the establishment of an Asia Research & Development (R&D) headquarters for innovative drug discovery and development located in Beijing, China. The new facility is part of a $1.5 billion commitment the company has made to invest in R&D in China over the next five years.
|
Nov 23 2011 | News
Results of a study published Wednesday in The Lancet suggest that the benefits of statin therapy in people at high risk of cardiovascular problems persist for at least five years after stopping treatment.
|